← Leaderboards
Wadih Arap
Rutgers Biomedical And Health Sciences
$12,814,372
Attributed
$18,832,765
Total exposure
16
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,832,765 · 16
By mechanism
R01$11,975,513 · 7
R33$2,938,479 · 2
U54$1,955,318 · 2
R21$1,671,648 · 4
P50$291,807 · 1
Top collaborators
- Renata Pasqualini26 shared
- C Jeffrey Brinker5 shared
- Vittorio Cristini5 shared
- Steven K. Libutti5 shared
- Dimitrios P Kontoyiannis2 shared
- Utz Herbig1 shared
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Renata Pasqualini$15,543,620
- Steven K. Libutti$7,794,095
Others in their field
Top investigators on “Ligands”
- John Damon Chodera · Sloan-Kettering Inst Can Research$39,009,297
- Keith W Miller · Massachusetts General Hospital$35,506,092
- Ian A Wilson · Scripps Research Institute, The$35,392,112
- Bryan L Roth · Univ Of North Carolina Chapel Hill$32,442,555
- Edward Franklin Plow · Cleveland Clinic Foundation$32,215,714
- Helen M Berman · Rutgers University New Brunswick$32,076,400
Research focus
LigandsIn VivoPhage DisplayMolecularBacteriophagesReceptorImageBaseTumorPeptidesDesignHomingTissuesCellsCell SurfacePropertyTechnologyParticleInsightLeadBlood VesselsSamplingIn VitroDisease Progression
Grant awards (53)
Identification of Molecular Features Associated with Vascular Alterations in Aging$431,750
R21 · FY2025 · AG
Ligand-directed therapeutic CRISPR/Cas gene editing in tumor cells$183,494
R21 · FY2025 · CA
Phage-based therapeutic gene delivery targeting multiple compartments in solid tumors$403,686
R21 · FY2024 · CA
Designing a transcriptome-based, targeted theranostic platform for prostate cancer$341,181
R01 · FY2024 · CA
Ligand-directed therapeutic CRISPR/Cas gene editing in tumor cells$220,193
R21 · FY2024 · CA
Designing a transcriptome-based, targeted theranostic platform for prostate cancer$351,955
R01 · FY2023 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$629,467
R01 · FY2022 · CA
Designing a transcriptome-based, targeted theranostic platform for prostate cancer$351,955
R01 · FY2022 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$642,358
R01 · FY2021 · CA
Targeting Lymphatic Vessels for Ligand Directed Imaging$363,713
R01 · FY2021 · CA
Designing a transcriptome-based, targeted theranostic platform for prostate cancer$358,185
R01 · FY2021 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$642,804
R01 · FY2020 · CA
Targeting Lymphatic Vessels for Ligand Directed Imaging$363,713
R01 · FY2020 · CA
Designing a transcriptome-based, targeted theranostic platform for prostate cancer$356,850
R01 · FY2020 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$623,916
R01 · FY2019 · CA
Targeting Lymphatic Vessels for Ligand Directed Imaging$352,801
R01 · FY2019 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$673,092
R01 · FY2018 · CA
Targeting Lymphatic Vessels for Ligand Directed Imaging$327,341
R01 · FY2018 · CA
Targeting Lymphatic Vessels for Ligand Directed Imaging$34,656
R01 · FY2018 · CA
Targeting Lymphatic Vessels for Ligand Directed Imaging$346,556
R01 · FY2017 · CA
Regulation of the paracrine angiogenic function of cardiac myocytes bycardiomyoc$366,250
R01 · FY2014 · HL · contact PI
Multifunctional Nanoassemblies for Ligand-directed Imaging and Therapy of Endocri$449,283
U54 · FY2013 · CA · contact PI
Regulation of the paracrine angiogenic function of cardiac myocytes bycardiomyoc$355,786
R01 · FY2013 · HL · contact PI
Regulation of the paracrine angiogenic function of cardiac myocytes by cardiomyoc$391,050
R01 · FY2012 · HL · contact PI
Multifunctional Nanoassemblies for Ligand-directed Imaging and Therapy of Endocri$318,072
U54 · FY2012 · CA · contact PI
Regulation of the paracrine angiogenic function of cardiac myocytes by cardiomyoc$395,000
R01 · FY2011 · HL · contact PI
Multifunctional Nanoassemblies for Ligand-directed Imaging and Therapy of Endocri$288,000
U54 · FY2011 · CA · contact PI
Novel Clinical Diagnostic Targets For Detection of Invasive Mold Aspergillosis$195,525
R21 · FY2011 · AI · contact PI
Regulation of the paracrine angiogenic function of cardiac myocytes by cardiomyoc$395,000
R01 · FY2010 · HL · contact PI
Multifunctional Nanoassemblies for Ligand-directed Imaging and Therapy of Endocri$306,459
U54 · FY2010 · CA · contact PI
Novel Clinical Diagnostic Targets For Detection of Invasive Mold Aspergillosis$237,000
R21 · FY2010 · AI · contact PI
Molecular Targeting of Lymphatic Endothelial Receptors for Ligand-directed Imagin$200,968
R01 · FY2010 · CA
Molecular Diversity in Bladder Cancer$308,686
R01 · FY2009 · DK · contact PI
Molecular Targeting of Lymphatic Endothelial Receptors for Ligand-directed Imagin$200,972
R01 · FY2009 · CA
Molecular Diversity in Bladder Cancer$308,686
R01 · FY2008 · DK · contact PI
Molecular Diversity in Bladder Cancer$314,986
R01 · FY2007 · DK · contact PI
MAPPING VACULAR DIVERSITY OF HUMAN CANCER$418,881
R33 · FY2006 · CA · contact PI
Imaging Tumor Blood Vessels in Bone Metastases from Breast Cancer$324,393
R01 · FY2006 · DK · contact PI
Molecular Diversity in Bladder Cancer$324,393
R01 · FY2006 · DK · contact PI
STEM CELL-BRAIN TUMOR INTERPLAY &IN VIVO PHAGE DISPLAY$567,796
R33 · FY2005 · CA
MAPPING VACULAR DIVERSITY OF HUMAN CANCER$416,735
R33 · FY2005 · CA
Imaging Tumor Blood Vessels in Bone Metastases from Breast Cancer$332,200
R01 · FY2005 · DK
Molecular Diversity in Bladder Cancer$332,200
R01 · FY2005 · DK
STEM CELL-BRAIN TUMOR INTERPLAY &IN VIVO PHAGE DISPLAY$554,611
R33 · FY2004 · CA
MAPPING VACULAR DIVERSITY OF HUMAN CANCER$410,708
R33 · FY2004 · CA
Imaging Tumor Blood Vessels in Bone Metastases from Breast Cancer$332,200
R01 · FY2004 · DK
STEM CELL-BRAIN TUMOR INTERPLAY &IN VIVO PHAGE DISPLAY$569,748
R33 · FY2003 · CA
Imaging Tumor Blood Vessels in Bone Metastases$332,200
R01 · FY2003 · DK
Molecular heterogeneity of tumor blood vessels$296,752
U54 · FY2002 · CA
BLOOD VESSEL TARGETING IN PROSTATE CANCER TREATMENT$291,807
P50 · FY2002 · CA
Molecular heterogeneity of tumor blood vessels$296,752
U54 · FY2001 · CA
Molecular heterogeneity of tumor blood vessels$0
U54 · FY2001 · CA
BLOOD VESSEL TARGETING IN PROSTATE CANCER TREATMENT$0
P50 · FY2001 · CA